Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Tax Provisions (2022 - 2025)

Gyre Therapeutics (GYRE) has disclosed Tax Provisions for 7 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Tax Provisions rose 7.88% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.6 million through Dec 2025, down 27.93% year-over-year, with the annual reading at $4.6 million for FY2025, 27.93% down from the prior year.
  • Tax Provisions for Q4 2025 was $1.3 million at Gyre Therapeutics, down from $1.7 million in the prior quarter.
  • The five-year high for Tax Provisions was $6.0 million in Q4 2022, with the low at $662000.0 in Q2 2025.
  • Average Tax Provisions over 4 years is $2.0 million, with a median of $1.5 million recorded in 2024.
  • The sharpest move saw Tax Provisions crashed 88.33% in 2023, then soared 72.39% in 2024.
  • Over 4 years, Tax Provisions stood at $6.0 million in 2022, then plummeted by 88.33% to $699000.0 in 2023, then skyrocketed by 72.39% to $1.2 million in 2024, then rose by 7.88% to $1.3 million in 2025.
  • According to Business Quant data, Tax Provisions over the past three periods came in at $1.3 million, $1.7 million, and $662000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.